Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Flonase Spanish-Language TV Ads Disclose No Risk Info - Warning Letter

Executive Summary

Glaxo Wellcome's Spanish-language broadcast advertisement for Flonase (fluticasone) failed to disclose any warning or risk information, FDA reported in an Aug. 18 warning letter to the company.

You may also be interested in...



FDA Response Time For DTC Ad Advisory Comments Has Doubled, Agency Says

FDA has increased from two to four weeks the time it takes to return direct-to-consumer broadcast ads with advisory comments due to the enlarged volume of submissions, Division of Drug Marketing, Advertising & Communications Branch Chief Nancy Ostrove, PhD, reported Sept. 13 at a Food & Drug Law Institute conference on "Marketing and Promotion in the New Millennium."

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
UsernamePublicRestriction

Register

PS034746

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel